Patent classifications
C07D251/48
ErbB/BTK inhibitors
Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
ErbB/BTK inhibitors
Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Guanidine compounds and use thereof
The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
Guanidine compounds and use thereof
The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with EGFR and/or HER2 activity.
CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R.sub.1, R.sub.2, R.sub.3, R.sub.3′, R.sub.4, R.sub.4′, R.sub.5, R.sub.6, R.sub.7, R.sub.8, m, and n are as defined in the detailed description.
##STR00001##
CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R.sub.1, R.sub.2, R.sub.3, R.sub.3′, R.sub.4, R.sub.4′, R.sub.5, R.sub.6, R.sub.7, R.sub.8, m, and n are as defined in the detailed description.
##STR00001##
N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer. ##STR00001##